Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 901–1,000 of 1,000
Manos, K., Chong, G., Keane, C., Lee, S.-T., Smith, C. D., Churilov, L. P., McKendrick, J. J., Renwick, W. E. P., Blombery, P. A., Burgess, M. L., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01863-7 · Cited by 16
“This approach is effective in lung and colon cancers, where neoadjuvant ICI induces higher responses in chemotherapy-naive patients, including subgroups not responsive to ICI in late-stage disease [16, 17].”
BackgroundZhang, L., Haoran, E., Huang, J., Wu, J., Li, Q., Hou, L., Li, C., Dai, C., Deng, J., Yang, M., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09910-8 · Cited by 19
Non-pharmaceutical interventions to optimize cancer immunotherapy
Boesch, M., Baty, F., Rassouli, F., Kowatsch, T., Joerger, M., Früh, M., & Brutsche, M. H. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2255459 · Cited by 19
“Conversely, the neoadjuvant treatment setting 103,104 seems to provide an opportune moment for ICB as microbiota and the immune system remain largely unperturbed from clinical intervention at this stage.”
BackgroundChen, Y., Ren, M.-Y., Li, B., Meng, Y., Wang, C., Jiang, P., Song, T.-N., Yang, J., Zhu, D., & Yu, Q. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1388 · Cited by 18
“The impressive outcomes of ICIs in neoadjuvant therapy for other solid tumors (8,9), where adverse reactions have also been controllable, have spurred growing interest in applying ICIs to neoadjuvant therapy for EC.”
BackgroundHuang, S., Huang, Y., Li, C., Liang, Y., Huang, M., Luo, R., & Liang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332213 · Cited by 16
Zhang, S., Tian, Y., Yu, J. X., Zhang, J.-H., Sun, L., Huang, L., Ma, J., & Han, C. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107799 · Cited by 16
Self-citationPerioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
Sa, H., Song, P., Ma, K., Gao, Y., Zhang, L., & Wang, D. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s222412 · Cited by 16
Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?
Arrieta, V. A., IWAMOTO, F. M., Lukas, R. V., Sachdev, S., Rabadán, R., & Sonabend, A. M. (2019) · Journal of neurosurgery · doi:10.3171/2019.9.jns192523 · Cited by 15
Amin, S., Baine, M. J., Meza, J. L., Alam, M., & Lin, C. H. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01569-5 · Cited by 17
Shui, L., Cheng, K., Li, X., Shui, P., Zhou, X., Li, J., Cheng, Y., & Cao, D. (2020) · BMC Cancer · doi:10.1186/s12885-020-07126-3 · Cited by 15
Zobel, M. J., Zamora, A. K., Wu, H., Sun, J., Lascano, D., Malvar, J., Wang, L. L., Sheard, M. A., Seeger, R. C., & Kim, E. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001560 · Cited by 16
Laser nanobubbles induce immunogenic cell death in breast cancer
Nguyen, H. T. M., Katta, N., Widman, J. A., Takematsu, E., Feng, X., Torres-Hurtado, S. A., Betancourt, T., Baker, A. B., Suggs, L. J., Milner, T. E., et al. (2021) · Nanoscale · doi:10.1039/d0nr06587k · Cited by 16
Hattori, A., Matsunaga, T., Takamochi, K., Oh, S., & Suzuki, K. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.03.232 · Cited by 15
Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer
Gutiérrez-Sainz, L., Cruz‐Castellanos, P., Higuera, O., & de Castro, J. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00885-6 · Cited by 18
Cai, G., Guan, Z., Jin, Y., Su, Z., Chen, X., Liu, Q., Wang, C., Yin, X., Zhang, L., Ye, G., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00120 · Cited by 19
“T cells play a key role in antitumor immune responses.(14-17) T-cell receptor (TCR) high-throughput sequencing (TCRHTS) can detect the sequence of the TCR repertoire and comprehensively assess the T-cell clonal composition and frequency.”
BackgroundIlié, M., Beaulande, M., Long-Mira, É., Bontoux, C., Zahaf, K., Lalvée, S., Hamila, M., Benzaquen, J., Cohen, C., Berthet, J., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.022 · Cited by 15
Donlon, N. E., Davern, M., Hayes, C., Power, R. F., Sheppard, A. D., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103729 · Cited by 15
Feng, Y., Yan, S., Lam, S. K., Ko, F. C. F., Chen, C., Khan, M., & Ho, J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.10.002 · Cited by 16
“Although PD-1/PD-L1 inhibitors have been approved for clinical use, only a small percentage of patients may bene t (3), prompting the development of novel therapeutic targets and combined techniques to broaden the population who may bene t.”
BackgroundNakajima, M., Hazama, S., Tokumitsu, Y., Shindo, Y., Matsui, H., Matsukuma, S., Nakagami, Y., Tamada, K., Udaka, K., Sakamoto, M., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13900 · Cited by 16
“Using immunotherapy in a preoperative setting could be attractive, because it can use the primary tumor as a source of antigen for the activation of tumor antigen‐specific T cells and for systemic immune surveillance against micrometastases.(28) However, neoadjuvant immunotherapy requires special caution, because seve…”
BackgroundWang, Y., Huang, S., Feng, X., Xu, W., Luo, R., Zhu, Z., Zeng, Q., & He, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145128 · Cited by 15
“One patient’s cPR neoantigen-specific T-cell clones rapidly increased in peripheral blood and were maintained for up to 4 weeks after treatment (32).”
BackgroundInfluentialZheng, Y., Feng, B., Chen, J., & You, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1273220 · Cited by 17
Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas
Suda, K., Shimoji, M., Shimizu, S., Sato, K., Chiba, M., Tomizawa, K., Takemoto, T., Soh, J., & Mitsudomi, T. (2019) · Biomolecules · doi:10.3390/biom9090456 · Cited by 16
Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy
Taugner, J., Käsmann, L., Eze, C., Dantes, M., Roengvoraphoj, O., Gennen, K., Karin, M., Petruknov, O., Tufman, A., Belka, C., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.09.19 · Cited by 15
Yang, Z., Liu, M.-N., Yu, J., Yang, Y., Chen, T., Han, Y., Zhu, L., Zhao, J., Fu, X., & Cai, X. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-896 · Cited by 17
“The results of these preliminary phase I and II studies suggest that immune checkpoint inhibitors (ICIs) are feasible and well tolerated in early NSCLC neoadjuvant therapy patients (11).”
BackgroundHusseini, K. E., Piton, N., Marchi, M. D., Grégoire, A., Vion, R., Blavier, P., Thiberville, L., Baste, J., & Guisier, F. (2021) · Cancers · doi:10.3390/cancers13194915 · Cited by 15
“Recent findings from large-scale clinical trials investigating neoadjuvant PD-1 blockade for the treatment of resectable NSCLC have shown encouraging results [8,9].”
BackgroundResultUnderstanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors
Sholl, L. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy227 · Cited by 15
Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?
Berghoff, A. S., & Preusser, M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0178-0 · Cited by 16
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?
Bilušić, M. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2069097 · Cited by 16
“due to disease progression, pseudoprogression, or treatment related adverse events [8].”
BackgroundHarnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy
Chiffelle, J., Genolet, R., Michielin, O. A., & Harari, A. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101076 · Cited by 17
“Esophageal 16 [62] 13 [105] 9 [109] 21 [110] 46 [82] 46 [82] 23 [108] 40 [86] 23 [108] 80 [91] 55 [106] 55 [106] 71 [112] 182 [31] 80 [91] 119 [97] 57 [99] 57 [99] 41 [100] 38 [115] 29 [101] 25 [107] 20 [114] 29 [101] 31 [102] 19 [90] 19 [90] 19 [90] 23 [89] 143 [103] 101 [94] 101 [94] 40 [95] 40…”
Rojas, F. R., Parra, E. R., Wistuba, I. I., Haymaker, C., & Soto, L. M. S. (2022) · Cancers · doi:10.3390/cancers14112775 · Cited by 21
“showed that, in a small set of 11 pretreatment sam‐ ples, TMB was strongly associated with pathological response [21,63].”
BackgroundMethodInfluentialZhao, G., Zhang, H., Xu, F., Lu, C., Zhu, Q., Grossi, F., Divisi, D., Ma, T., Gu, J., & Ge, D. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-871 · Cited by 16
“6%) achieved CPR, comparable to other previous trials ranging between 12% and 63% (8), which is higher than the 10.”
BackgroundMethodReview of cancer therapies for the perioperative physician
Dabo-Trubelja, A., & Gottumukkala, V. N. R. (2023) · Perioperative Medicine · doi:10.1186/s13741-023-00315-1 · Cited by 14
“Results favor combining these two treatment modalities to improve cancer outcomes (Forde et al. 2018).”
BackgroundT-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC
Yi, L., Xu, Z., Ma, T., Wang, C., Wei, P., Xiao, B., Zhang, H., Che, N., Liu, Z., & Han, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03687-5 · Cited by 18
“…reached 62% (26/42), and pCR was achieved in 45% (19/42) of patients after treat-ment, which was also higher than that of chemotherapy or ICI neoadjuvant therapy, such as the neoadjuvant chemotherapy group of CheckMate -816 (37% of MPR, 2% of pCR) and CheckMate-159 (45% of MPR, 15% of pCR) [8, 24].”
BackgroundResultAokage, K., Koyama, S., Kumagai, S., Nomura, K., Shimada, Y., Yoh, K., Wakabayashi, M., Fukutani, M., Furuya, H., Miyoshi, T., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1561 · Cited by 16
Shobab, L. A., Al-Souri, D., Mathews, L., McCoy, M., Kuenstner, W., Hubbard, G. K., Kumari, S., Chou, J., Lee, W., Rosen, J. E., et al. (2024) · Cancers · doi:10.3390/cancers16213632 · Cited by 14
Li, H., Gong, Y., Yan, P., Xu, Y. J., Qin, G., Wen, W., & Teng, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1453753 · Cited by 23
Wu, Y., Shang, J., Zhang, X., & Li, N. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02940-4 · Cited by 18
Yang, L., Yang, H., Zhao, M., Yuan, H., Geng, J., Yan, Y., Li, W., Xing, L., Yu, J., & Sun, X. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00831-x · Cited by 17
Fu, R., Wu, L., Zhang, C., Chu, Q., Hu, J., Lin, G., Yang, L., Li, J., Yang, X., Yang, J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100053 · Cited by 19
Single‐Domain Antibody‐Based TCR‐Like CAR‐T: A Potential Cancer Therapy
Zhu, L., Yang, X., Zhong, D., Xie, S., Shi, W., Li, Y., Hou, X., HuaYao, Zhou, H., Zhao, M., et al. (2020) · Journal of Immunology Research · doi:10.1155/2020/2454907 · Cited by 17
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer
Fournel, L., Boudou, P., Prieto, M., Hervochon, R., Guinet, C., Arrondeau, J., Alexandre, J., Damotte, D., Wislez, M., Batteux, F., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04142-9 · Cited by 14
Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non–Small-Cell Lung Cancer
Kamigaichi, A., Tsutani, Y., Mimae, T., Miyata, Y., Shimada, Y., Ito, H., Nakayama, H., Ikeda, N., & Okada, M. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.010 · Cited by 15
Jia, W., Zhu, H., Gao, Q., Sun, J., Tan, F., Liu, Q., Guo, H., & Yu, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633534 · Cited by 16
“This phenomenon has also been observed in pancreatic cancer and NSCLC after neoadjuvant therapy (30, 31).”
BackgroundSelf-citationHuang, Z., Wu, Z., Qin, Y., Zhao, Y., Xuan, Y., Qiu, T., Liu, A., Dong, Y., Su, W., Du, W., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1141 · Cited by 17
“%) of 24 patients who underwent surgery had a MPR, and 1 (4.2”
BackgroundInfluentialTian, X., Wang, T., Zheng, Q., Tao, Y., Dai, L., & Shen, H. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14317 · Cited by 15
Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer
Xu, K., Yang, H., Ma, W., Fan, L., Sun, B., Wang, Z., Al-Hurani, M. F., Schmid, R. A., & Yao, F. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1195 · Cited by 15
“The pathological response was graded according to the Junker criteria and assessed in all resected specimens (18).”
MethodGene Expression Profiles of Multiple Synchronous Lesions in Lung Adenocarcinoma
Lim, J., Han, Y. B., Park, S. Y., Ahn, S., Kim, H., Kwon, H. J., Lee, C., Cho, S., & Chung, J.-H. (2021) · Cells · doi:10.3390/cells10123484 · Cited by 14
“However, surgical intervention is a standard treatment for early-stage NSCLC, while the introduction of immunotherapy into the treatment of early-stage NSCLC remains in the experimental stages [40].”
BackgroundLoick, S. M., Fröhlich, A., Gabrielpillai, J., Franzen, A., Vogt, T. J., Dietrich, J., Wiek, C., Scheckenbach, K., Strieth, S., Landsberg, J., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000407 · Cited by 16
“GITR: cg13360866 (1), cg24807889 (2), cg05952202 (3), cg04172501 (4), cg22696995 (5), cg23400617 (6), cg06778273 (7), cg18319381 (8), cg19413397 (9), cg12810734 (10), cg08090128 (11), cg16046810 (12), cg19237691 (13), cg08641866 (14), cg15706223 (15), cg14886269 (16), cg06097659 (17), cg04343794 (18), cg07671976 (19),…”
Hu, C., Shu, L., Chen, C., Fan, S., Liang, Q., Zheng, H., Pan, Y., Zhao, L., Zou, F., Liu, C., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-751 · Cited by 16
“However, it should be noted that the benefits for stage IB patients were not as good as stage II/IIIA (5-7).”
BackgroundSu, P., Chen, J., Chu, C., Chen, Y., Chen, W.-L., Lin, K., Ho, C., Tsai, J., Yang, S., Chen, C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07423-w · Cited by 16
Self-citationChen, C., Wang, Q., Zhou, D., 黄晓洁, Zhao, Z., Qian, B., Wu, F., Chen, J., Liang, Q., Jiang, Y., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-023-01422-y · Cited by 16
“CXCR2 in NSCLC has been studied mainly in stromal cells and was known to increase tumor inflammation and angiogenesis.”
BackgroundFang, M., Hang, Q., Jiang, H., Cai, L., Hu, J., Ying, H., Gu, Q., Yu, X., Liu, J., & Lai, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1055610 · Cited by 14
“In general, most studies choose two to four doses, whereas CheckMate159 (12) and LCMC3 (19) trials chose two doses, NADIM (9) and CheckMate 816 trials were of three doses, and NCT02716038 trial (10) was of four doses.”
BackgroundMethodFrancisco‐Cruz, A., Rocha, P., Reuben, A., Krishnan, S., Das, P., Chen, R., Quek, K., Li, J., Parra, E. R., Solis, L. M., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100028 · Cited by 17
Self-citationChen, J., Han, Y., Hu, Y., Feng, X., Meng, X., Guo, S., Sun, C., Chen, G., & Li, K. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-067767 · Cited by 17
“PD-1 inhibitor monotherapy has achieved a 40%–45% major pathological response and 15%–16% pCR in resectable NSCLC. 29 33 Contrarily, in the NADIM Study, patients receiving nivolumab combined with NACT showed a major pathological response of 83%, of whom 63% had a complete pathological response.”
BackgroundZhang, J., Quadri, S. A., Wolfgang, C. L., & Zheng, L. (2018) · Biomedicines · doi:10.3390/biomedicines6030087 · Cited by 18
Self-citationReassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019
Psutka, S. P., Chang, S. L., Cahn, D. B., Uzzo, R. G., & McGregor, B. A. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237453 · Cited by 16
Mitchell, L., Yagiz, K., Hofacre, A., Viaud, S., Munday, A. W., Espinoza, F. L., Mendoza, D., Rodriguez-Aguirre, M. E., Bergqvist, S., Haghighi, A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26785 · Cited by 14
“RRV-scFv-PDL1 could potentially be applicable in a neoadjuvant setting prior to tumor resection; this type of use with nivolumab, was recently reported to induce expansion of antigen-specific clones in lung cancer [49].”
BackgroundLymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer
Mitchell, K. G., Negrao, M. V., Parra, E. R., Li, J., Zhang, J., Dejima, H., Vaporciyan, A. A., Swisher, S. G., Weissferdt, A., Antonoff, M. B., et al. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.08.029 · Cited by 14
“As immune checkpoint inhibitors continue to be explored in the setting of early NSCLC, an ability to identify patient subgroups most likely to derive therapeutic benefit from these agents is greatly needed (9, 10).”
BackgroundSelf-citationNeoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario
Kumar, S., Saikia, J., Kumar, V., Malik, P. S., Madan, K., Jain, D., & Bharati, S. J. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100563 · Cited by 15
Liquid biopsy is a valuable tool in the diagnosis and management of lung cancer
Cecchini, M. J., & Yi, E. S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.20 · Cited by 16
“Treatment with immunotherapy has been shown to improve the survival of patients with advanced (75) as well as early stage tumors with activity in the neoadjuvant setting (76).”
BackgroundSepesi, B., Cascone, T., Chun, S. G., Altan, M., & Le, X. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.06.009 · Cited by 15
Aronson, S. L., Thijssen, B., López‐Yurda, M., Koole, S. N., van der Leest, P., León‐Castillo, A., Harkes, R., Seignette, I. M., Sanders, J., Alkemade, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58440-y · Cited by 16
“Recent studies across various cancer types have reported remarkable pathologic responses with neo-adjuvant ICI therapy 18,20 – 24 .”
Hoeijmakers, L. L., Dimitriadis, P., Wijnen, S. C. M. A., Reijers, I. L. M., López‐Yurda, M., Menzies, A. M., Broeks, A., Cornelissen, S., Acosta, A. T., van der Wal, A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04158-9 · Cited by 15
Chen, J., Deng, H., He, J., Wang, Z., & Li, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909726 · Cited by 13
“5 (693) Median (Min, Max) 400 (22, 1,120) 505 (10, 2,000) 660 (10, 3,830) Postoperative hospital stay (days) 0.”
Chen, X., Bai, G., Zang, R., Song, P., Bie, F., Huai, Q., Li, Y., Liu, Y., Zhou, B., Bie, Y., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101725 · Cited by 16
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer
Conroy, M. R., Dennehy, C., & Forde, P. M. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107314 · Cited by 13
Self-citationSu, S., Chen, F., Lv, X., Liang, Q., Ding, Z., Ren, W., Wei, M., Liu, Y., Yu, L., Liu, B., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03620-2 · Cited by 16
“Immunotherapy has caused a transformation in the TCR repertoire, with early changes in TCR clonality correlating with the immune response, thus influencing the clinical outcomes of anti-PD-1/PD-L1 treat-ment in NSCLC [33, 37–40].”
BackgroundImmune checkpoint inhibition in early-stage non-small cell lung cancer
Cuppens, K., Pont, B. D., Knegjens, J., Maes, B., & Baas, P. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107855 · Cited by 18
Liver resection and transplantation in the era of checkpoint inhibitors
Tabrizian, P., Marino, R., & Chow, P. K. H. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101181 · Cited by 22
“18 – 20 The goal is to facilitate curative surgery by identifying effective immunotherapeutic and combination strategies to reduce historically high recurrence rates and to serve as a downstaging therapy.”
Novel therapeutic approaches for non-small cell lung cancer: an updated view
Orooji, N., Babaei, S., Fadaee, M., Abbasi‐Kenarsari, H., Eslami, M., Kazemi, T., & Yousefi, B. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2489986 · Cited by 15
“…findings that nivolumab treatment causes a significant increase in cD8 + t cells in the resected tumour and peripheral blood following surgery [100]. in another study in phase ib, a total of 40 NSclc patients in stages iA to iiiB were given 2 doses of a PD-1 inhibitor called sintilimab every…”
InfluentialLiu, G., Chen, T., Li, R., Zhu, L. X., Liu, D., & Ding, Z. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12799 · Cited by 13
Changes in store for early-stage non-small cell lung cancer
Sandler, J. E., D’Aiello, A., & Halmos, B. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.34 · Cited by 13
“Forde and colleagues treated a cohort of 22 patients with resectable stage I-IIA NSCLC with 2 cycles of nivolumab prior to surgical resection (23).”
BackgroundImmunotherapy for Neuro-Oncology
Majd, N., Dasgupta, P., & de Groot, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_8 · Cited by 16
Mielgo-Rubio, X., Rojo, F., Mezquita-Pérez, L., Casas, F., Wals-Zurita, A., Juan, M., Aguado, C., Garde, J., Vicente, D., & Couñago, F. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i11.898 · Cited by 13
Calvo, V., Aliaga, C., Carracedo, C. F., & Provencio, M. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-515 · Cited by 16
“Typical ly, we use computed tomography (CT) to evaluate the response to treatment, also to neoadjuvant treatment, but there have been disagreements between the histopathological response rate and the response measured by RECIST which varies between 35% and 41% (23,24).”
MethodWan, Y., Ge, K., Zhou, W., Lu, J., Jia, C., & Zhu, H. (2021) · Biological Chemistry · doi:10.1515/hsz-2020-0328 · Cited by 13
Wang, N., Wang, R., Zhang, X., Li, X., Liang, Y., & Ding, Z. (2021) · Visualized Cancer Medicine · doi:10.1051/vcm/2020002 · Cited by 14
Göker, E., Altwairgi, A. K., Al-Omair, A., Tfayli, A., Black, E., Elsayed, H. H., Selek, U., & Koegelenberg, C. F. N. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.025 · Cited by 14
Safety Analysis of Salvage Surgery for Advanced Stages or Metastatic Lung Cancers
Bertolaccini, L., Galetta, D., Sedda, G., de Marinis, F., & Spaggiari, L. (2021) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/s-0041-1730968 · Cited by 13
Faehling, M., Fallscheer, S., Kramberg, S., Sträter, J., Eschmann, S. M., Sätzler, R., & Heinzelmann, F. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.07.035 · Cited by 14
Ali, W. A. S., Hui, P., Ma, Y., Wu, Y., Zhang, Y., Chen, Y., Hong, S., Yang, Y., Huang, Y., Zhao, Y., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1702 · Cited by 13
“Consistent with previous studies, our results showed that high TMB was significantly associated with improved PFS (20,21); however, the role of TMB as a predictive marker of OS in patients treated with ICIs remains unclear.”
ResultExploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
Roller, J., Veeramachaneni, N. K., & Zhang, J. (2022) · Cancers · doi:10.3390/cancers14030741 · Cited by 14
“(2018) [23] Phase II Stage I–IIIA Resectable NSCLC, 21 (4/10/7) 2 cycles (3 mg/kg every 2 weeks) nivolumab pre-operatively Approximately 4 weeks after the first dose of Nivolumab 20 (95%)/21 18 days No treatmentrelated delays 0%/0% (One patient without recurrence died from a traumatic head injury that was unrelated to…”
BackgroundInfluentialSelf-citationNeoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
Yao, Y., Tang, D., Gao, W., & Zhang, H. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.843987 · Cited by 13
Barshidi, A., Karpisheh, V., Noukabadi, F. K., Kiani, F. K., Mohammadi, M. K., Afsharimanesh, N., Ebrahimi, F., Kiaie, S. H., Navashenaq, J. G., Hojjat‐Farsangi, M., et al. (2021) · Pharmaceutical Research · doi:10.1007/s11095-022-03297-9 · Cited by 13
RetractedOncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis
Zhao, X., Chen, Y., Sun, X., He, Z., Wu, T., Wu, C., Chen, J., Wang, J., Diao, K., & Liu, X. (2022) · Cancers · doi:10.3390/cancers14174226 · Cited by 13
Shao, L., & Lou, G. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1192 · Cited by 14
“(22,23) demonstrated that there was a substantial expansion of CD8 cells in the resected tumors and post-surgery peripheral blood.”
InfluentialYi, W., Qiao, T., Yang, Z., Hu, L., Sun, M., Fan, H., Xu, Y., & Lv, Z. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100470 · Cited by 13
Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy
Wu, Y., & Feng, L. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2168640 · Cited by 13
Wu, C., Shao, Y., & Gu, W. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03091-y · Cited by 16
“After the initial success of immunotherapy for melanoma [11] and lung cancer [12, 13], immunotherapy has become a recognized treatment method for various solid tumors [14].”
BackgroundTao, Y., Li, X., Liu, B., Wang, J., Lv, C., Li, S., Wang, Y., Chen, J., Yan, S., & Wu, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1135140 · Cited by 14
“Other biomarkers like TMB, MIS-H or PD-L1 expression couldn’t effectively predict the outcome of neoadjuvant immunotherapy (5, 7).”
BackgroundClinical implications of aberrant PD-1 expression for acute leukemia prognosis
Ruan, Y., Wang, J., Zhang, Q., Wang, H., Li, C., Xu, X., & Zhai, Z. (2023) · European journal of medical research · doi:10.1186/s40001-023-01352-8 · Cited by 16
Self-citationTian, W., Niu, L., Wang, Z., Lu, R., Xiao, G., Deng, F., Tanzhu, G., & Zhou, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1268070 · Cited by 15
Su, Y., Liu, C., Lu, X., Chuang, H.-Y., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71349-4 · Cited by 14
“The staining protocol followed the Perki-nElmer Opal staining kit manual and previous studies 67 .”
Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon
Helmink, B. A., Roland, C. L., Kiernan, C. M., & Wargo, J. A. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08183-0 · Cited by 13
“In a recent study of 21 patients with stages 1 to 3A NSCLC treated with neoadjuvant anti-PD-1 therapy, Forde et al.(38) demonstrated no surgical delays and low grade 3 toxicity rates.”
BackgroundAmin, S., Baine, M. J., Meza, J. L., & Lin, C. H. (2020) · BMC Cancer · doi:10.1186/s12885-020-07016-8 · Cited by 13
Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer
Guo, H., Li, W., Qian, L., & Cui, J. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.02.08 · Cited by 14
Self-citationSato, M., Umeda, Y., Tsujikawa, T., Mori, T., Morikawa, M., Anzai, M., Waseda, Y., Kadowaki, M., Kiyono, Y., Okazawa, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003079 · Cited by 14
“19 20 However, to date, there is no report applying 18 F-FLT PET imaging to evaluate early responses to immunotherapy for NSCLC.”
InfluentialImmunotherapy for Stage III NSCLC: Durvalumab and Beyond
Fitzpatrick, O., & Naidoo, J. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s305466 · Cited by 17
Self-citationFaehling, M., Witte, H. M., Sebastian, M., Ulmer, M., Sätzler, R., Steinestel, K., Brückl, W. M., Evers, G., Büschenfelde, C. M. Z., & Bleckmann, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221085333 · Cited by 14
Ye, Q., & Guo, N. L. (2022) · Cancers · doi:10.3390/cancers14133123 · Cited by 13
“Immunotherapy has shown promising results in NSCLC [6,7].”
Background
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.